|
Inhibitors of TRIP8b for Novel Mood Disorder Therapeutics
SHORT DESCRIPTION
Novel inhibitors that disrupt TRIP8b-HCN binding to offer an alternative antidepressant mechanism for treatment of mood disorders.
INVENTORS
Gary Schiltz*
Weinberg College of Arts and Sciences, Department of Chemistry
Dane Chetkovich
Ye Han
Iredia Iyamu
Kyle Lyman
*...
Published: 6/17/2026
|
Updated: 6/17/2026
|
Inventor(s):
Keywords(s): Antidepressant, BIO2026, Depression, Mood disorder, Neurologic disease, Neurology, Psychiatric disorder, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
A CSF-Derived Therapy for Psychiatric Disorders
SHORT DESCRIPTION
A synthetic soluble ⍺2δ-1-Fc protein to restore brain function in schizophrenia and autism.
INVENTORS
Peter Penzes*
Northwestern University Feinberg School of Medicine, Department of Physiology
Marc Dos Santos
* Principal Investigator
NU Tech ID: NU 2023-196
IP STATUS
US...
Published: 6/16/2026
|
Updated: 6/10/2026
|
Inventor(s):
Keywords(s): ASD - Autism Spectrum Disorder, BIO2026, Biologic, Neurologic disease, Neurology, PSD - Psychotic spectrum disorder, Psychiatric disorder, Schizophrenia, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Novel Aminotransferase Inhibitor Platform for the Treatment of Cancer and Neurological Disorders
SHORT DESCRIPTION
Novel Aminotransferase Mechanism-Based Inhibitor (MBI) Platform Targeting OAT and GABA-AT as Novel Treatments for Cancer and Neurological Disorders.
INVENTORS
Richard Silverman*
Weinberg College of Arts and Sciences, Department of Chemistry
* Principal Investigator
DEVELOPMENT...
Published: 6/17/2026
|
Updated: 6/1/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, BIO2026, Cancer/Oncology, CNS - Central Nervous System, Colon cancer, Epilepsy, Gastric cancer, Liver cancer, Lung cancer, Neurodegenerative disease, Neurologic disease, Neurology, Pancreatic cancer, PD - Parkinson's Disease, Psychiatric disorder, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Novel Serotonin Receptor Agonist to Treat Neurological Disease
NU 2018-135
INVENTORS
Karl Scheidt*
Adam Csakai
Herbert Meltzer
SHORT DESCRIPTION
A novel small molecule that selectively targets serotonin 5-HT2c receptors for the treatment of psychiatric, mental, and/or neurological diseases.
BACKGROUND
Serotonin is a neurotransmitter known to regulate a variety of neurological functions, and alterations in...
Published: 7/1/2026
|
Updated: 2/23/2026
|
Inventor(s):
Keywords(s): BIO2026, Neurodegenerative disease, Neurologic disease, Psychiatric disorder, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
|